These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16315030)

  • 1. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
    Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
    Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
    Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
    Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.
    Otto K; Andersen MH; Eggert A; Keikavoussi P; Pedersen LØ; Rath JC; Böck M; Bröcker EB; Straten PT; Kämpgen E; Becker JC
    Vaccine; 2005 Jan; 23(7):884-9. PubMed ID: 15603888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
    Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
    Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel survivin-derived CTL epitopes.
    Reker S; Meier A; Holten-Andersen L; Svane IM; Becker JC; thor Straten P; Andersen MH
    Cancer Biol Ther; 2004 Feb; 3(2):173-9. PubMed ID: 14726703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
    Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
    Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
    Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
    Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
    Casati C; Dalerba P; Rivoltini L; Gallino G; Deho P; Rini F; Belli F; Mezzanzanica D; Costa A; Andreola S; Leo E; Parmiani G; Castelli C
    Cancer Res; 2003 Aug; 63(15):4507-15. PubMed ID: 12907624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B35-restricted immune responses against survivin in cancer patients.
    Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
    Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.
    Leisegang M; Wilde S; Spranger S; Milosevic S; Frankenberger B; Uckert W; Schendel DJ
    J Clin Invest; 2010 Nov; 120(11):3869-77. PubMed ID: 20978348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
    Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.